☆ 4.7 Review

Advances in research on potential inhibitors of multiple myeloma

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Related references

Note: Only part of the references are listed.

Article Chemistry, Multidisciplinary

Fluorine-containing drugs approved by the FDA in 2021

Jingrui He et al.

Summary: This review article presents nine newly approved fluorine-containing drugs by the US Food and Drug Administration (FDA) in 2021. These small molecule drugs feature aromatic fluo-rine, trifluoromethyl, and chlorodifluoro groups. The therapeutic areas of these fluorine-containing drugs include multiple myeloma, lymphoma, HIV, chronic heart failure, chronic myeloid leukemia, (ANCA)-associated vasculitis, migraines, von Hippel-Lindau disease, and non-small cell lung cancer. The review also discusses the brief biological activities and synthetic methods for each of these nine drugs.

CHINESE CHEMICAL LETTERS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

BRD4 and MYC: power couple in transcription and disease

Aparna Kotekar et al.

Summary: The MYC proto-oncogene and BRD4 protein play essential roles in cell biology and disease, with their functions and regulation closely interlinked. They regulate gene expression, maintain chromatin structure, and ensure genome stability, and dysregulation can lead to diseases, particularly cancer.

FEBS JOURNAL (2023)

Add to Collection

Letter Hematology

A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma

Robert Frank Cornell et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Oncology

Role of KSP Inhibitors as Anti-Cancer Therapeutics: An Update

Rinkal Chamariya et al.

Summary: Despite the side effects, conventional cytotoxic therapy targeting actively dividing cancer cells still plays a significant role in cancer treatment. Researchers have been developing novel microtubule motor protein inhibitors to overcome the limitations of traditional drugs. Kinesin spindle proteins have emerged as promising targets for cancer therapeutics.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Oncology

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

Sachi Morita et al.

Summary: LCL161, an oral IAP antagonist, enhances the activity of paclitaxel in cell lines and xenograft models. A phase I study was conducted to evaluate the combination of LCL161 and paclitaxel in Japanese patients with advanced solid tumors. Although the study was terminated early, it suggests a potential increase in infection risk with this combination therapy.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers

Uttam Sharma et al.

Summary: LINC01133 has been identified as a novel transcript in cancers, playing a significant role in modulating various cancer hallmarks. It serves as both an oncogenic and tumor-suppressive factor in different types of cancers. The expression of LINC01133 is correlated with tumor characteristics and patient survival. The authors propose LINC01133 as a potential biomarker and therapeutic target in cancer.

BIOMARKERS IN MEDICINE (2022)

Add to Collection

Article Oncology

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Cristina Gasparetto et al.

Summary: The study evaluated the safety and efficacy of the XKd regimen in patients with relapsed refractory MM, and found it to be highly effective and well-tolerated, supporting further investigation of this regimen in MM patients.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Precisely engineering a dual-drug cooperative nanoassembly for proteasome inhibition-potentiated photodynamic therapy

Fujun Yang et al.

Summary: This study presents a facile dual-drug nanoassembly that enhances the efficacy of photodynamic therapy by inhibiting the proteasome. The engineered nanoassembly demonstrates multiple advantages, including simple fabrication, high drug co-loading efficiency, flexible dose adjustment, and favorable stability and enrichment.

CHINESE CHEMICAL LETTERS (2022)

Add to Collection

Review Chemistry, Medicinal

A review on the treatment of multiple myeloma with small molecular agents in the past five years

Zhenzhen Zhang et al.

Summary: Multiple myeloma is currently incurable, and scientists are working on developing drugs with higher specificity to improve treatment outcomes.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Nonselective proteasome inhibitors in multiple myeloma and future perspectives

Maria Gavriatopoulou et al.

Summary: Proteasome inhibitors have shown efficacy in inhibiting tumor cell proliferation, with currently approved drugs including bortezomib, carfilzomib, and ixazomib. However, these inhibitors lack specificity and can cause side effects, leading to research on developing selective proteasome inhibitors for improved safety in the future.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Add to Collection

Article Cell Biology

TLR4-IN-C34 Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses via Downregulating TLR4/MyD88/NF-kappa B/NLRP3 Signaling Pathway and Reducing ROS Generation in BV2 Cells

Shan-Shan Zhang et al.

Summary: TLR4-IN-C34 exhibits anti-neuroinflammatory activity through inhibition of the TLR4/MyD88/NF-κB/NLRP3 signaling pathway and reducing ROS production in BV2 cells stimulated by LPS.

INFLAMMATION (2022)

Add to Collection

Review Oncology

Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy

Meng Zhang et al.

Summary: GLI inhibitors have great potential in various cancer treatments, effectively inhibiting the self-renewal of cancer stem cells and addressing issues such as tumor growth, metastasis, and drug resistance.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Management of Multiple Myeloma A Review

Andrew J. Cowan et al.

Summary: Multiple myeloma is a hematologic malignancy characterized by abnormal plasma cells in the bone marrow, often leading to anemia, bone disease, and kidney injury. Diagnosis involves measuring various biomarkers, while treatment options include chemotherapy, autologous hematopoietic stem cell transplantation, and maintenance therapy.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Oncology

Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs

Ilaria Saltarella et al.

Summary: The crosstalk between multiple myeloma cells and bone marrow fibroblasts plays a crucial role in disease progression and drug resistance. Researchers have found that MM cell-derived exosomes can reprogram the miRNA profile of fibroblasts, and tumor cells can neutralize exosomal miRs through lncRNA expression to ensure their survival.

JOURNAL OF PATHOLOGY (2022)

Add to Collection

Review Oncology

Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms

Suresh Kumar Balasubramanian et al.

Summary: Novel targeted therapeutics, particularly XPO1 inhibitors, have the potential to improve the management of hematological neoplasms by inhibiting multiple tumorigenic processes and enhancing the effects of other antineoplastic agents. However, the heterogeneity of driver lesions and multiple resistance pathways remain significant challenges.

LEUKEMIA (2022)

Add to Collection

Review Pharmacology & Pharmacy

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

Robert Roskoski

Summary: Due to the dysregulation of protein kinase activity, this enzyme family has become one of the most important drug targets in the 21st century. There are 68 FDA-approved therapeutic agents that target protein kinases, with six new drugs approved in 2021. These drugs are mainly used in the treatment of neoplasms and inflammatory diseases, with 58 drugs prescribed for tumor treatment. In addition, 18 drugs are used for the treatment of multiple diseases. This review summarizes the physicochemical properties of all FDA-approved small molecule protein kinase inhibitors.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Article Oncology

Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment

Yuko Tanaka et al.

Summary: This study found that S1P activation is associated with proliferation and survival of MM cells, and S1P attenuates the effect of proteasome inhibitors (PI). Anti-S1P agents can inhibit MM cell proliferation, promote apoptosis, and reduce the impact of S1P on cell migration. These findings highlight the potential therapeutic value of anti-S1P agents in MM treatment.

ONCOLOGY LETTERS (2022)

Add to Collection

Article Oncology

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma

Darren Pan et al.

Summary: Filanesib demonstrates safety and promising activity in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma. Patients with 1q21 gain and t(11;14) show particularly encouraging progression-free survival rates.

CANCER MEDICINE (2022)

Add to Collection

Article Oncology

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Melissa K. Bennett et al.

Summary: The introduction of the proteasome inhibitor bortezomib has improved patient survival in myeloma, but acquired resistance remains a challenge. Researchers have found that inhibiting sphingolipid metabolism can resensitize bortezomib-resistant myeloma, and this approach also works with other proteasome inhibitors like carfilzomib.

NEOPLASIA (2022)

Add to Collection

Article Hematology

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth

Lea Lemaitre et al.

Summary: TLR4 gene is upregulated in abnormal BM mesenchymal stromal cells (MSCs) in multiple myeloma (MM), and its inhibition reduces MM cell growth and delays disease progression.

BLOOD ADVANCES (2022)

Add to Collection

Review Medicine, Research & Experimental

Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies

Rand Shahin et al.

Summary: Halting the cell cycle in mitosis and interfering with its normal progression is an effective anti-cancer strategy. Traditional anti-cancer drugs directly inhibit microtubules during cell division, but they have serious side effects. On the other hand, KSP inhibitors are receiving attention as less toxic mitotic inhibitors. This review tracks the medicinal chemistry developmental stages of KSP inhibitors and discusses the challenges and future insights in developing active KSP inhibitor drugs for cancer treatment.

FUTURE SCIENCE OA (2022)

Add to Collection

Review Oncology

Promising Role of Phytochemicals in the Prevention and Treatment of Cancer

Aziz Unnisa et al.

Summary: Cancer has a significant social consequence globally, leading to increased interest in non-synthetic and alternative therapies. Natural remedies play a crucial role in cancer chemoprevention, but further clinical trials are needed.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted Protein Degradation and Regulation with Molecular Glue: Past and Recent Discoveries

Yizheng Fang et al.

Summary: This article provides an overview of the development of molecular glues and discusses the application of thalidomide and its derivatives as molecular glues. Researchers are actively exploring the mechanisms of new molecular glues and proposing methods for identifying novel molecular glues to promote further investigations in this field.

CURRENT MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Toll-like receptors: New targets for multiple myeloma treatment?

Olaia Akesolo et al.

Summary: Despite biomedical improvements, multiple myeloma remains incurable. Dysregulated signalling of Toll like receptors (TLRs) may play a critical role in its progression. Strategic targeting of TLRs could improve treatment response and reduce relapses.

BIOCHEMICAL PHARMACOLOGY (2022)

Add to Collection

Article Hematology

Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial

Sudhir Kumar et al.

Summary: This study evaluated the role of bendamustine, pomalidomide, and dexamethasone combination therapy in patients with resistant/refractory multiple myeloma. The results showed an overall response rate of 57.6% and median progression-free survival of 6.2 months. The combination therapy was well-tolerated with manageable toxicity.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Effects of polyphenols on ncRNAs in cancer-An update

Vishnu Priya Veeraraghavan et al.

Summary: This review discusses the potential role of plant polyphenols in cancer treatment and the regulatory role of long non-coding RNAs in tumorigenesis and development, suggesting that polyphenols may facilitate epigenetic modifications through interactions with cellular signaling pathways, contributing to the intervention of chronic diseases such as cancer.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells

Bingxue Qu et al.

Summary: Multiple myeloma is a highly malignant hematologic cancer with limited treatment options. The XPO1 inhibitor D4 has shown promising anti-proliferative effects and ability to induce apoptosis in tumor cells, indicating its potential for further drug development and clinical application.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Article Hematology

Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way

Domenica Giannandrea et al.

Summary: Multiple myeloma (MM) is an incurable hematologic neoplasm with poor prognosis, largely due to the interaction between MM cells and the bone marrow microenvironment. Researchers have found that MM-derived extracellular vesicles (MM-EV) contain the oncogenic NOTCH receptors, which play a crucial role in promoting the protumorigenic activity of MM-EV. These EV can transfer NOTCH2 between cells and increase NOTCH signaling in target cells, leading to increased angiogenesis and osteoclast differentiation. Targeting the NOTCH pathway may be a promising therapeutic strategy to inhibit the protumorigenic role of EV in MM and other tumors.

HAEMATOLOGICA (2022)

Add to Collection

Article Hematology

Multiple myeloma with high-risk cytogenetics and its treatment approach

Ichiro Hanamura

Summary: This paper reviews the clinicopathological features of genomic abnormalities related to adverse prognosis, focusing on high-risk cytogenetic abnormalities in newly diagnosed multiple myeloma patients, and outlines the optimal therapeutic approaches. Achieving sustained minimal residual disease has been shown to improve patient outcomes.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Oncology

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies

Samantha Bruno et al.

Summary: CDC20 plays an important role in regulating the cell cycle and its abnormal functionality has been associated with cancer development and poor survival. Recent studies have revealed additional functions of CDC20, including apoptosis regulation, stemness properties, and correlation with immune cell infiltration. Investigating the network of interacting proteins of CDC20 provides insight into its role in mitosis and beyond. Furthermore, CDC20 expression and its association with prognosis in hematological malignancies have attracted increasing attention.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Mechanisms of non-coding RNA-modulated alternative splicing in cancer

Xiaolin Wang et al.

Summary: Alternative splicing is a crucial process in the regulation of gene expression in eukaryotes, playing a pivotal role in cancer. Non-coding RNAs, including miRNAs, lncRNAs, and circRNAs, have been found to be involved in modulating alternative splicing in human cancers, with regulatory functions in tumorigenesis.

RNA BIOLOGY (2022)

Add to Collection

Article Oncology

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction

Hayley M. Sabol et al.

Summary: In multiple myeloma, Notch3 signaling plays a crucial role in promoting tumor growth and bone destruction. Inhibiting Notch3 can reduce MM cell proliferation and decrease their osteoclastogenic potential. Notch3 acts as a mediator of cell communication between multiple myeloma cells and osteocytes.

NEOPLASIA (2022)

Add to Collection

Article Oncology

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma

Stephanie Kadow et al.

Summary: Kv1.3 channels are identified as a potential therapeutic target for multiple myeloma. The mitochondria-specific Kv1.3 inhibitors, PAPTP and PCARBTP, effectively kill myeloma cells while sparing healthy bone marrow cells. Combination with the BCL-2 inhibitor venetoclax shows a synergistic effect.

CANCERS (2022)

Add to Collection

Article

Cancer Chemotherapy via Natural Bioactive Compounds

Kalyani Pathak et al.

Current Drug Discovery Technologies (2022)

Add to Collection

Article Oncology

Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma

Haiqin Wang et al.

Summary: Multiple myeloma, the second most common hematological malignancy, remains incurable despite improved survival rates with new clinical agents. This study identified polyphyllin VII as a promising compound that selectively suppresses multiple myeloma cell growth by targeting moesin, a critical regulator of the Wnt/beta-catenin pathway. Polyphyllin VII induces moesin degradation via the ubiquitin-proteasome pathway, impairing Wnt/beta-catenin pathway activity and overcoming bortezomib resistance.

CANCER LETTERS (2022)

Add to Collection

Article Chemistry, Medicinal

Novel insights on [1,2]oxazolo[5,4-e]isoindoles on multidrug resistant acute myeloid leukemia cell line

Manuela Labbozzetta et al.

Summary: A series of newly synthesized [1,2]oxazolo[5,4-e]isoindole derivatives showed antiproliferative activities against HL-60 and HL-60R cells, with compound 4k exhibiting synergistic effects in combination with Vinblastine and Paclitaxel. All compounds demonstrated antimitotic activity through inhibition of tubulin polymerization.

DRUG DEVELOPMENT RESEARCH (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting the Microenvironment for Treating Multiple Myeloma

Peter Neumeister et al.

Summary: Multiple myeloma (MM) is a malignant and incurable disease characterized by the interaction between tumor cells and the bone marrow microenvironment. Therapeutic interventions targeting the bone marrow microenvironment have become a novel strategy for treating multiple myeloma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

CircRNAs: novel therapeutic targets in multiple myeloma

Xinyi Zhou et al.

Summary: circRNA, as a type of non-coding RNA, is closely associated with the incidence and progression of MM. This review summarizes the biological properties and functions of circRNA in MM, and discusses its clinical utility in the diagnosis, prognosis, and treatment of MM.

MOLECULAR BIOLOGY REPORTS (2022)

Add to Collection

Article Oncology

Advances in the treatment of extramedullary disease in multiple myeloma

Yating Li et al.

Summary: This review summarizes the recent advances in the treatment of extramedullary disease (EMD) in multiple myeloma (MM) patients. Bortezomib-based therapy and immunomodulatory drugs have shown efficacy, while marizomib has advantages in treating CNS-MM. Isatuximab and selinexor also exhibit activity. However, the benefits of novel drugs for EMD patients are limited.

TRANSLATIONAL ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Josh N. Vo et al.

Summary: In this study, genomic and transcriptomic profiling of 511 relapsed and refractory multiple myeloma (MM) patients revealed genetic alterations in several oncogenic pathways contributing to disease progression and resistance to MM therapies.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Shaji Kumar et al.

Summary: This article discusses the treatment options and strategies for Multiple Myeloma, highlighting the lack of curative methods and the possibility of relapse and drug resistance over time. The selection of alternative treatments in these cases is challenging and requires further clinical trials and research.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Review Cell Biology

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives

Gary Alvarez Bravo et al.

Summary: Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) play an important role in the immune system, especially in relation to multiple sclerosis. Modulation of S1P has potential significance for treating autoimmune disorders.

CELLS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Polyphenols as Potent Epigenetics Agents for Cancer

Peramaiyan Rajendran et al.

Summary: Polyphenols play a major role in mammalian epigenome regulation through mechanisms and proteins that remodel chromatin. They are found in fruits, seeds, vegetables, and food supplements, and have powerful anticancer effects. This article summarizes the role of polyphenols in restoring epigenetic alterations in cancer cells and discusses their molecular targets in cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Combination Therapy Using Polyphenols: An Efficient Way to Improve Antitumoral Activity and Reduce Resistance

Alina Florentina Vladu et al.

Summary: Polyphenols have shown potential as antineoplastic agents in cancer treatment. They can be combined with cytostatic drugs to enhance therapeutic effects and protect healthy cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma

Katia Grillone et al.

Summary: A novel compound, SIX2G, was synthesized and found to inhibit cell viability, induce the expression of CD86 and CD69, and enhance the phagocytosis of tumor cells. These findings suggest the potential immunogenicity and anti-MM activity of SIX2G.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Biochemical Research Methods

Advances in detecting N6-methyladenosine modification in circRNAs

Lixia Ma et al.

Summary: circRNAs are a class of noncoding RNAs with important biological functions, where m6A modification plays a crucial role in regulation. Accurate identification of m6A modification in circRNAs is a key step in research in this field.

METHODS (2022)

Add to Collection

Review Oncology

Long non-coding RNAs interact with RNA-binding proteins to regulate genomic instability in cancer cells

Kai Yang et al.

Summary: This review examines the roles of genomic instability and lncRNAs in cancer, focusing on the mechanisms by which lncRNAs regulate genomic instability by binding proteins. It enhances our understanding of cancer development and provides potential targets for cancer therapies.

ONCOLOGY REPORTS (2022)

Add to Collection

Review Immunology

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Qing Tang et al.

Summary: PD-1 and PD-L1 play important roles in the progression of human cancers and are promising biomarkers for cancer therapy. The interaction between PD-1 and PD-L1 is a crucial mechanism by which human tumors evade the immune system. PD-1/PD-L1 immune-checkpoint inhibitors have shown promising therapeutic effects in human cancers, with combination therapy and predictive models as potential future directions.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Hematology

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Sagar Lonial et al.

Summary: This study evaluated the safety and clinical activity of Iberdomide plus dexamethasone in heavily pretreated patients with relapsed or refractory multiple myeloma. The combination therapy showed meaningful clinical activity and was generally safe in this patient population.

LANCET HAEMATOLOGY (2022)

Add to Collection

Review Cell Biology

Modern aspects of the use of natural polyphenols in tumor prevention and therapy

Galina Sufianova et al.

Summary: Polyphenols are beneficial compounds synthesized by plants that have antioxidant and anti-inflammatory effects. They help fight cell damage and have a potential preventive effect on certain forms of cancer by influencing the complex processes of tumor development.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Targeted Covalent Inhibition: A Prospective Way to Develop Novel HSP90 C-terminal Inhibitor

Yajun Liu et al.

CURRENT DRUG TARGETS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

Ian D. Ferguson et al.

Summary: Heat shock protein 70 (HSP70) chaperones have been identified as potential targets for overcoming proteasome inhibitor (PI)-induced stress in multiple myeloma. Allosteric HSP70 inhibitors (JG compounds) show increased efficacy against PI-resistant myeloma by impacting mitochondrial-localized HSP70. These findings highlight the importance of HSP70 and suggest HSPA9 as a specific vulnerability in PI-resistant disease.

CELL CHEMICAL BIOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

BRD4: a general regulator of transcription elongation

Elisabeth Altendorfer et al.

Summary: Transcription elongation by Pol II is a crucial control point in gene expression. Pausing of Pol II near the promoter region is regulated by various factors, including BRD4, which has recently been identified as a general regulator of transcription elongation.

TRANSCRIPTION-AUSTIN (2022)

Add to Collection

Article Immunology

Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis

Poyee Lau et al.

Summary: This study reveals the important role of SPHK1 in tumor immunity and shows that its inhibition can suppress tumor growth and promote antitumor immunity. Additionally, SPHK1 and MTA3 are identified as biological markers for predicting the efficacy of anti-PD-1 mAb therapy in melanoma patients.

CELLULAR & MOLECULAR IMMUNOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Potential roles and molecular mechanisms of phytochemicals against cancer

Zhaodi Zheng et al.

Summary: Increasing evidence supports the therapeutic functions of phytochemicals in treating human diseases, especially cancer. These plant secondary metabolites have shown promising anti-cancer efficacy with high efficiency and low toxicity. They regulate various signaling pathways to inhibit cancer development and can be combined with chemotherapeutic agents for a novel therapeutic strategy.

FOOD & FUNCTION (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Notch signaling pathway: architecture, disease, and therapeutics

Binghan Zhou et al.

Summary: The NOTCH gene and signaling pathway have been studied for 110 years and play important roles in the development, homeostasis, and related diseases of tissues and organs. However, recent studies have found that the outcomes of NOTCH signaling are context-dependent. In terms of cancer, NOTCH signaling can both promote and inhibit tumor development. NOTCH-targeted therapies in clinical trials have not met expectations, and NOTCH mutations may serve as predictive biomarkers for immune checkpoint blockade therapy in many cancers.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection

Review Hematology

The Association between Metabolic Syndrome and Multiple Myeloma

Sophie C. Ragbourne et al.

Summary: Multiple myeloma is a hematological malignancy involving monoclonal proliferation of plasma cells leading to the presence of paraproteins in serum. There is a connection between paraproteins, metabolic syndrome features, inflammatory cytokines, and the development of MM. Some drugs used in treating metabolic syndrome, such as statins and metformin, may improve outcomes in MM.

ACTA HAEMATOLOGICA (2021)

Add to Collection

Review Oncology

Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma

Yang Bai et al.

Summary: Proteasome inhibitors (PIs) have been crucial therapies for myeloma patients, targeting the overstressed 26S proteasome involved in the disease pathogenesis. However, the major limitation in PI therapy lies in the acquisition of resistance, despite recent advancements in clinical antimyeloma treatment.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Complex crosstalk of Notch and Hedgehog signalling during the development of the central nervous system

Craig T. Jacobs et al.

Summary: The development of the vertebrate central nervous system is tightly regulated by highly conserved cell signalling pathways, with Notch and Hedgehog pathways playing key roles. These pathways interact in a complex manner throughout CNS development, with Notch signaling often regulating Hedgehog response and vice versa. The intricate crosstalk between Notch and Hedgehog pathways highlights the interconnectivity and context-dependent modes of interaction between them, within a wider, multi-pathway signalling network.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Roles of miRNA dysregulation in the pathogenesis of multiple myeloma

Dan Chen et al.

Summary: miRNAs play a critical role in regulating pathological factors involved in the progression of multiple myeloma, including bone marrow microenvironment, methylation, immune regulation, genomic instability, and drug resistance. They also have potential as novel prognostic biomarkers and therapeutic targets.

CANCER GENE THERAPY (2021)

Add to Collection

Article Oncology

Albendazole inhibits NF-KB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma

Hui Yi et al.

Summary: This study demonstrates the potential therapeutic effects of albendazole on multiple myeloma by inhibiting MM cell proliferation, reducing the number of MMSCs, and eliminating drug resistance induced by MMSCs through the inhibition of the NF-KB pathway.

CANCER LETTERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists

Ali Keshavarz et al.

Summary: TLRs play a crucial role in immune system, but misregulation is linked to cancer development. Aberrant expression of TLRs allows cancer cells to escape immune surveillance and promotes proliferation and angiogenesis.

IUBMB LIFE (2021)

Add to Collection

Review Rheumatology

Toll-like receptor signalling in B cells during systemic lupus erythematosus

Simon Fillatreau et al.

Summary: Loss of B cell tolerance to autoantigens in systemic lupus erythematosus (SLE) is driven by TLR7, whereas TLR9 appears to protect against SLE by limiting the stimulatory activity of TLR7. The unique features of Toll-like receptor signaling in B cells implicate it as a therapeutic target in SLE.

NATURE REVIEWS RHEUMATOLOGY (2021)

Add to Collection

Review Genetics & Heredity

Histone Ubiquitination: An Integrative Signaling Platform in Genome Stability

Francesca Mattiroli et al.

Summary: This passage discusses the mechanisms in place to maintain genome stability, focusing on the central role of chromatin ubiquitination. It reviews specific histone ubiquitination events within the cellular DNA damage response, with emphasis on the recent discovery of Ub phosphorylation as a novel regulator. Exciting open questions for future research on the implications of histone (phospho)ubiquitination on chromatin structure are highlighted.

TRENDS IN GENETICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Ferroptosis Induction in Multiple Myeloma Cells Triggers DNA Methylation and Histone Modification Changes Associated with Cellular Senescence

Emilie Logie et al.

Summary: This study indicates that inducing ferroptosis and epigenetic reprogramming by RSL3 can sensitize MM1 multiple myeloma cells, regardless of their glucocorticoid-sensitivity status. Analysis revealed the formation of non-heme iron-histone complexes and altered expression of histone modifications associated with DNA repair and cellular senescence.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Letter Oncology

WDR26 and MTF2 are therapeutic targets in multiple myeloma

Fumou Sun et al.

Summary: The study utilized unbiased genetic forward screening in a genetically engineered mouse model of multiple myeloma to discover two novel myeloma genes: WDR26 and MTF2. These findings suggest that WDR26-CTLH and MTF2-PRC2 could be promising molecular targets for new approaches to myeloma treatment and prevention.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Characterization of PMI-5011 on the regulation of deubiquitinating enzyme activity in multiple myeloma cell extracts

Manibarathi Vaithiyanathan et al.

Summary: Deubiquitinating enzyme (DUB)-targeted therapeutics have shown promise as alternative cancer treatments, with the botanical extract PMI-5011 found to positively regulate DUB activity in two multiple myeloma cell lines. Additionally, bioactive compounds in PMI-5011 showed similar effects on DUB activity, suggesting therapeutic potential in cancer treatment.

BIOCHEMICAL ENGINEERING JOURNAL (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Long non-coding RNA XIST: a novel oncogene in multiple cancers

Jun Yang et al.

Summary: X-inactive specific transcript (XIST) is a crucial long non-coding RNA derived from the XIST gene in mammals, and it is abnormally expressed in numerous tumors where it acts as an oncogene. This review analyzes recent studies on the impact of XIST in human tumor development, aiming to clarify the pathologic mechanisms and provide a novel direction for further study.

MOLECULAR MEDICINE (2021)

Add to Collection

Article Hematology

A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma

Shinsuke Iida et al.

Summary: The study aimed to determine the maximum tolerated dose and recommended dose for expansion of PIM447 in Japanese patients with relapsed and/or refractory MM. Results showed that PIM447 at 250 mg or 300 mg once daily was tolerated in patients, with common adverse events including thrombocytopenia, anemia, and leukopenia. Further studies are needed to evaluate clinical outcomes of PIM447 in combination with other drugs for MM treatment.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs

Konstantin Byrgazov et al.

LEUKEMIA RESEARCH (2021)

Add to Collection

Article Oncology

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

David L. Murray et al.

Summary: Mass spectrometry is emerging as a powerful tool in diagnosing and monitoring plasma cell disorders, showing equivalent clinical performance to immunofixation electrophoresis with added benefits of detecting additional risk factors and differentiating therapeutic antibodies. This technology is gaining traction in clinical laboratories and may become the new standard in practice.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting oncoproteins with a positive selection assay for protein degraders

Vidyasagar Koduri et al.

Summary: Some undruggable proteins can be targeted by compounds that degrade them. Current assays for identifying degraders have limitations, but a new gain of signal assay has been developed to facilitate the discovery of drugs that degrade undruggable proteins directly or indirectly.

SCIENCE ADVANCES (2021)

Add to Collection

Article

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan

Erling Håland et al.

Oncotarget (2021)

Add to Collection

Review Oncology

Targeting cell-cycle machinery in cancer

Jan M. Suski et al.

Summary: Abnormal activity of the core cell-cycle machinery drives tumorigenesis in most tumor types, with cell-cycle proteins regulating a wide range of cellular functions in addition to cell division. Inhibiting different cell-cycle proteins shows potential as an effective anti-cancer strategy, as evidenced by the clinical success of CDK4/6 inhibitors.

CANCER CELL (2021)

Add to Collection

Article Pharmacology & Pharmacy

Melphalan Flufenamide (Melflufen): First Approval

Sohita Dhillon

Summary: Melphalan flufenamide, a peptide conjugated alkylating drug, has shown promising results in the treatment of multiple myeloma and amyloid light-chain amyloidosis. Its rapid transport across cell membranes and conversion to active alkylating agents make it a valuable option for patients with refractory diseases. Ongoing clinical trials and preclinical studies indicate potential applications in various hematological and solid cancers.

DRUGS (2021)

Add to Collection

Article Chemistry, Medicinal

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold

Chaodong Xiong et al.

Summary: NEDD8 plays a crucial role in the functional maintenance and homeostasis of cells, with dysregulation implicated in various human diseases. Therefore, developing new NAE inhibitors with high potency and better safety profiles is urgently needed.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Oncology

JunB is a key regulator of multiple myeloma bone marrow angiogenesis

Fengjuan Fan et al.

Summary: This study demonstrates a significant correlation between JunB and angiogenic factors in MM, independent of hypoxia. JunB plays a dual role as a mediator of MM cell survival, proliferation, drug resistance, and also promotes angiogenesis in the BM microenvironment. These findings suggest targeting JunB as a potential strategy in MM therapy.

LEUKEMIA (2021)

Add to Collection

Review Hematology

Immunomodulators in newly diagnosed multiple myeloma: current and future concepts

Michel Delforge et al.

Summary: This review discusses the role of IMiDs in the treatment of multiple myeloma, especially in managing newly diagnosed patients. Current research indicates that treatment regimens combining IMiDs with proteasome inhibitors and MoAbs show the most significant efficacy in MM patients.

EXPERT REVIEW OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Genetic variants as biomarkers for progression and resistance in multiple myeloma

Rachel A. Montel et al.

Summary: Technical advances in genome sequencing, particularly whole-genome sequencing, provide tools for understanding cancer at the molecular level, with a focus on genetic variants associated with pathogenic cancers like multiple myeloma. Protein-coding genes such as NRAS, KRAS, TP53, and others are found to be responsible for cell cycle regulation in multiple myeloma, and their mutations are characterized using software tools like Qiagen's IPA and IVA. Gene network associations and cancer driver variants in MM have been investigated, shedding light on the genetic mechanisms underlying the disease.

CANCER GENETICS (2021)

Add to Collection

Article Oncology

Resveratrol for cancer therapy: Challenges and future perspectives

Boxu Ren et al.

Summary: Despite its potential anticancer effects, resveratrol faces obstacles in clinical translation due to poor pharmacokinetics, low potency, and nephrotoxicity in certain patients. New strategies to enhance its bioavailability and develop more potent analogues are proposed to overcome these challenges and advance resveratrol in cancer therapy.

CANCER LETTERS (2021)

Add to Collection

Review Oncology

Roadmap to cure multiple myeloma

Paula Rodriguez-Otero et al.

Summary: In order to achieve a cure for multiple myeloma, five complementary strategies are proposed: increasing knowledge about disease pathogenesis, using undetectable measurable residual disease as the new endpoint of therapy, treating disease causation instead of symptomatology, using the most active scheme, and investigating experimental therapies.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Medical Laboratory Technology

PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival

Yaqiong Li et al.

Summary: The study found that increased expression of PHF19 is associated with poor treatment response and unfavorable long-term prognosis in patients with multiple myeloma.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2021)

Add to Collection

Review Immunology

Toll-Like Receptors: General Molecular and Structural Biology

Payam Behzadi et al.

Summary: TLRs play a crucial role in bridging innate and adaptive immune systems through activation by various molecular patterns. Their unique properties present opportunities for the development of ligand-drug discovery strategies.

JOURNAL OF IMMUNOLOGY RESEARCH (2021)

Add to Collection

Review Pharmacology & Pharmacy

The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition

Michael A. Serwetnyk et al.

Summary: Hsp90 is a crucial molecular chaperone with potential as a target for cancer therapy. In addition to known inhibitory mechanisms, alternative approaches for Hsp90 inhibition are being explored.

ACTA PHARMACEUTICA SINICA B (2021)

Add to Collection

Article Oncology

SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma

Jian Wu et al.

Summary: This study explores the role of SMAD1 in multiple myeloma (MM), identifying critical axes of MM drug resistance and proposing a potentially new therapeutic strategy to treat drug-resistant MM through targeted inhibition of SMAD1.

BIOMARKER RESEARCH (2021)

Add to Collection

Article Hematology

IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB- and caspase-8-dependent mechanisms

Liang Zhou et al.

Summary: The combination of LCL161 and LBH589 showed synergistic interactions in inducing apoptosis in human multiple myeloma cells by inactivating the noncanonical NF-kappa B pathway and activating the extrinsic apoptotic pathway. This treatment strategy was effective in primary MM cells and overcame various forms of resistance, demonstrating significant anti-tumor activity in vivo, suggesting its potential as a novel therapeutic approach in MM.

BLOOD ADVANCES (2021)

Add to Collection

Review Immunology

Immunotherapy of Multiple Myeloma: Promise and Challenges

Hanley N. Abramson

Summary: The treatment landscape for multiple myeloma has evolved significantly over the years, with the introduction of new classes of drugs and immunotherapies. While survival rates have improved and quality of life has been enhanced, the disease remains incurable, emphasizing the need for further innovation in therapies.

IMMUNOTARGETS AND THERAPY (2021)

Add to Collection

Review Oncology

PIM Kinases in Multiple Myeloma

Jian Wu et al.

Summary: Multiple myeloma is a common hematologic malignancy with patients often developing resistance to current treatments. PIM kinases play a crucial role in the pathogenesis and relapse of myeloma, making the development of novel PIM kinase inhibitors significant for potential treatment strategies.

CANCERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways

Jiaxin Liu et al.

Summary: The immune system acts as a fortress against pathogens and tumor cells, but excessive immune responses can lead to harmful effects. Therapeutic antibodies targeting immune checkpoints have made breakthroughs in cancer treatment, but the efficacy of immune checkpoint blockade remains unsatisfactory.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting ubiquitin signaling for cancer immunotherapy

Xiaofei Zhou et al.

Summary: Cancer immunotherapy has achieved great success in treating advanced malignancies, with immune checkpoint inhibitors being a remarkable advancement. Research on protein ubiquitination as potential targets for enhancing antitumor immunity is an active area of investigation.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Oncology

The nuclear export protein XPO1-from biology to targeted therapy

Asfar S. Azmi et al.

Summary: XPO1 plays a crucial role in cellular homeostasis and cancer development, with its inhibitor selinexor clinically validated and approved for multiple myeloma and diffuse large B cell lymphoma treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Artemisinin-type drugs for the treatment of hematological malignancies

R. Mancuso et al.

Summary: Qinghaosu, known as artemisinin, has been used in traditional Chinese medicine for over two millennia and is now a standard treatment for malaria worldwide. In addition to its anti-malarial properties, it also exhibits anticancer activities, particularly against hematologic malignancies. The chemical structure of artemisinin contains an endoperoxide bridge essential for its activity, and it works through mechanisms such as oxidative stress response, inhibition of proliferation, and induction of various types of cell death. Research on new pharmaceutically active compounds based on artemisinin could potentially enhance existing therapeutic alternatives for combating hematologic malignancies.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

W. Larry Gluck et al.

INVESTIGATIONAL NEW DRUGS (2020)

Add to Collection

Review Pharmacology & Pharmacy

Proteasome Inhibitor Drugs

Lloyd D. Fricker

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)

Add to Collection

Article Medicine, Research & Experimental

Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells

Mitsuki Tabata et al.

CLINICAL AND EXPERIMENTAL MEDICINE (2020)

Add to Collection

Article Cell Biology

Proteasome inhibition in multiple myeloma: lessons for other cancers

Paula Saavedra-Garcia et al.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

Silpa Narayanan et al.

DRUG RESISTANCE UPDATES (2020)

Add to Collection

Article Pharmacology & Pharmacy

Selinexor for the treatment of multiple myeloma

Klaus Podar et al.

EXPERT OPINION ON PHARMACOTHERAPY (2020)

Add to Collection

Article Oncology

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Eric K. Rowinsky et al.

INVESTIGATIONAL NEW DRUGS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival

Yuanming He et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Chemistry, Medicinal

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Joshua D. Hansen et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

Robert Roskoski

PHARMACOLOGICAL RESEARCH (2020)

Add to Collection

Review Hematology

Heat shock proteins as a new, promising target of multiple myeloma therapy

Sebastian Grosicki et al.

EXPERT REVIEW OF HEMATOLOGY (2020)

Add to Collection

Review Oncology

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

Meletios A. Dimopoulos et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Review Chemistry, Multidisciplinary

Small-Molecule Modulators of Toll-like Receptors

Yibo Wang et al.

ACCOUNTS OF CHEMICAL RESEARCH (2020)

Add to Collection

Article Hematology

The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells

Xiaoxiao Wu et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Hematology

The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma

Long Liang et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Immunology

Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy

Ji-Yoon Noh et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2020)

Add to Collection

Article Immunology

Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases

Lizdany Florez-Alvarez et al.

IMMUNOTHERAPY (2020)

Add to Collection

Article Oncology

Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a

Tengteng Yu et al.

MOLECULAR CANCER RESEARCH (2020)

Add to Collection

Review Biochemistry & Molecular Biology

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Sajid Khan et al.

ONCOGENE (2020)

Add to Collection

Review Pharmacology & Pharmacy

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

G. R. Tundo et al.

PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Cell Biology

A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma

Zhihua Zhang et al.

CELL CYCLE (2020)

Add to Collection

Review Immunology

Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy

Yun Yang et al.

IMMUNOLOGY LETTERS (2020)

Add to Collection

Article Oncology

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Nina Shah et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy

Nicola Manfrini et al.

CANCER RESEARCH (2020)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Prospecting for molecular glues

Willem den Besten et al.

NATURE CHEMICAL BIOLOGY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Exploring the proteasome system: A novel concept of proteasome inhibition and regulation

Xinyuan Wang et al.

PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Belantamab Mafodotin: First Approval

Anthony Markham

DRUGS (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

Panagiotis Malandrakis et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Article Medicine, Research & Experimental

SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation

Yu Xiang et al.

LIFE SCIENCES (2020)

Add to Collection

Review Oncology

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

Nicholas Theodoropoulos et al.

TARGETED ONCOLOGY (2020)

Add to Collection

Review Hematology

Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma

Slavisa Ninkovic et al.

EXPERT REVIEW OF HEMATOLOGY (2020)

Add to Collection

Review Oncology

Immune-based therapies in the management of multiple myeloma

Saurabh Zanwar et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Review Chemistry, Medicinal

Ubiquitin-proteasome system (UPS) as a target for anticancer treatment

Jinyoung Park et al.

ARCHIVES OF PHARMACAL RESEARCH (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The role of ubiquitination in tumorigenesis and targeted drug discovery

Lu Deng et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Hematology

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis

Guang Li et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)

Add to Collection

Review Hematology

Glucocorticoids in multiple myeloma: past, present, and future

Nicholas Burwick et al.

ANNALS OF HEMATOLOGY (2019)

Add to Collection

Article Immunology

The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing

Rosa Molfetta et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2019)

Add to Collection

Article Chemistry, Multidisciplinary

Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis

Xue-han Chen et al.

ACTA PHARMACOLOGICA SINICA (2019)

Add to Collection

Review Cell Biology

Inhibitors of nuclear transport

David A. Jans et al.

CURRENT OPINION IN CELL BIOLOGY (2019)

Add to Collection

Review Oncology

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

Ola Landgren et al.

LEUKEMIA (2019)

Add to Collection

Review Immunology

The Membrane-Associated MARCH E3 Ligase Family: Emerging Roles in Immune Regulation

Heng Lin et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Review Genetics & Heredity

The biogenesis, biology and characterization of circular RNAs

Lasse S. Kristensen et al.

NATURE REVIEWS GENETICS (2019)

Add to Collection

Article Medicine, General & Internal

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Multidisciplinary Sciences

Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15

Arjan Mofers et al.

PLOS ONE (2019)

Add to Collection

Review Hematology

The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma

David Vrabel et al.

BLOOD REVIEWS (2019)

Add to Collection

Article Multidisciplinary Sciences

DPP8 is a novel therapeutic target for multiple myeloma

Tsutomu Sato et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Oncology

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Drew W. Rasco et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Letter Hematology

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis

Lenka Besse et al.

HAEMATOLOGICA (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?

Naresh Poondla et al.

BMB REPORTS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents

Chandrasekaran Balakumar et al.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2018)

Add to Collection

Article Multidisciplinary Sciences

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance

Jinfang Zhang et al.

NATURE (2018)

Add to Collection

Review Hematology

Resistance to proteasome inhibitors and other targeted therapies in myeloma

Craig T. Wallington-Beddoe et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted protein degradation and the enzymology of degraders

Stewart L. Fisher et al.

CURRENT OPINION IN CHEMICAL BIOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

Proteasome inhibitors for the treatment of multiple myeloma

Emilia Scalzulli et al.

EXPERT OPINION ON PHARMACOTHERAPY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Ubiquitination: Friend and foe in cancer

Mohammed A. Mansour

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Quality Control in the Endoplasmic Reticulum: Crosstalk between ERAD and UPR pathways

Jiwon Hwang et al.

TRENDS IN BIOCHEMICAL SCIENCES (2018)

Add to Collection

Article

Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3

Jing Ma et al.

TUMOR BIOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

The molecular basis of JAK/STAT inhibition by SOCS1

Nicholas P. D. Liau et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Review Oncology

Drug resistance in multiple myeloma

Pawel Robak et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection

Review Pharmacology & Pharmacy

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy

Tao Yuan et al.

FRONTIERS IN PHARMACOLOGY (2018)

Add to Collection

Article Chemistry, Medicinal

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenannide)

Henry W. B. Johnson et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

Add to Collection

Article Multidisciplinary Sciences

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Adriana E. Tron et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Meeting Abstract Hematology

Efficacy and Safety of Histone Deacetylase Inhibitors in Multiple Myeloma - a Systematic Review of Early Phase Clinical Trials

Sharoon Samuel et al.

BLOOD (2018)

Add to Collection

Article Hematology

A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results

Andrew Spencer et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Article Cell Biology

TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses

Nicholas J. Hess et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2017)

Add to Collection

Article Oncology

Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects

Haiming Chen et al.

MOLECULAR CANCER RESEARCH (2017)

Add to Collection

Article Biochemical Research Methods

Overview of the membrane-associated RING-CH (MARCH) E3 ligase family

Johannes Bauer et al.

NEW BIOTECHNOLOGY (2017)

Add to Collection

Article Oncology

A Phase 1 and 2 Study of Filanesib Alone and in Combination With Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma

Jatin J. Shah et al.

CANCER (2017)

Add to Collection

Article Oncology

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

J. Cavenagh et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells

Deepika Sharma Das et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Hematology

Marizomib for central nervous system-multiple myeloma

Ashraf Badros et al.

BRITISH JOURNAL OF HAEMATOLOGY (2017)

Add to Collection

Article Oncology

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Article Oncology

Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier

Kaijun Di et al.

NEURO-ONCOLOGY (2016)

Add to Collection

Article Oncology

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

Susanne Lub et al.

ONCOTARGET (2016)

Add to Collection

Review Pharmacology & Pharmacy

Multifaceted ability of naturally occurring polyphenols against metastatic cancer

Qingyu Zhou et al.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Proteostasis regulation by the ubiquitin system

John S. Bett

PROTEOSTASIS (2016)

Add to Collection

Article Biochemistry & Molecular Biology

IAP antagonists induce anti-tumor immunity in multiple myeloma

Marta Chesi et al.

NATURE MEDICINE (2016)

Add to Collection

Article Oncology

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkBa and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Joel G. Turner et al.

ONCOTARGET (2016)

Add to Collection

Article Hematology

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

Luke F. Peterson et al.

BLOOD (2015)

Add to Collection

Article Biochemistry & Molecular Biology

KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway

In-Sung Song et al.

BMB REPORTS (2015)

Add to Collection

Article Oncology

Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma

M. Hiasa et al.

LEUKEMIA (2015)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

The ubiquitin-proteasome-system Preface

Thomas Sommer et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)

Add to Collection

Article Hematology

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

Yanyan Gu et al.

BLOOD (2014)

Add to Collection

Review Hematology

Targeting the ubiquitin proteasome system in haematological malignancies

Lisa J. Crawford et al.

BLOOD REVIEWS (2013)

Add to Collection

Article Dermatology

Impaired Proteasome Function Activates GATA3 in T Cells and Upregulates CTLA-4: Relevance for Sezary Syndrome

Heather M. Gibson et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)

Add to Collection

Review Biochemistry & Molecular Biology

USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy

Iraia Garcia-Santisteban et al.

MOLECULAR CANCER (2013)

Add to Collection

Article Oncology

Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells

Helena Mistry et al.

MOLECULAR CANCER THERAPEUTICS (2013)

Add to Collection

Article Multidisciplinary Sciences

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

Qingxiang Sun et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

Article Oncology

Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma

Jill Corre et al.

CANCER RESEARCH (2012)

Add to Collection

Review Immunology

Ubiquitination in signaling to and activation of IKK

Zhijian J. Chen

IMMUNOLOGICAL REVIEWS (2012)

Add to Collection

Review Biochemistry & Molecular Biology

GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness

Chan C. Whiting et al.

FEBS JOURNAL (2011)

Add to Collection

Article Oncology

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

J. Asano et al.

LEUKEMIA (2011)

Add to Collection

Article Hematology

Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappa B

Yang Xu et al.

BRITISH JOURNAL OF HAEMATOLOGY (2010)

Add to Collection

Review Oncology

Targeting the dynamic HSP90 complex in cancer

Jane Trepel et al.

NATURE REVIEWS CANCER (2010)

Add to Collection

Review Biochemistry & Molecular Biology

The emerging complexity of protein ubiquitination

David Komander

BIOCHEMICAL SOCIETY TRANSACTIONS (2009)

Add to Collection

Article Multidisciplinary Sciences

Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks

Yaron Galanty et al.

NATURE (2009)

Add to Collection

Article Multidisciplinary Sciences

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Teresa A. Soucy et al.

NATURE (2009)

Add to Collection

Review Hematology

Multiple myeloma

Robert A. Kyle et al.

BLOOD (2008)

Add to Collection

Article Multidisciplinary Sciences

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

MS Cohen et al.

SCIENCE (2005)

Add to Collection

Article Immunology

Cutting edge:: Cbl-b:: One of the key molecules tuning CD28- and CTLA-4-Mediated T cell costimulation

DD Li et al.

JOURNAL OF IMMUNOLOGY (2004)

Add to Collection

Article Cell Biology

A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition

L Coscoy et al.

JOURNAL OF CELL BIOLOGY (2001)

Add to Collection

Article Medicine, Research & Experimental

A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation

L Coscoy et al.

JOURNAL OF CLINICAL INVESTIGATION (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.